Challenges of recurrent hepatitis C in the liver transplant patient

Table 1 Clinical outcome of treatment for post-transplant hepatitis C recurrence

Ref.	I	Study design	SVR	Fibrosis progression	Discontinuance
Roche et al[85] (2008)	113	Retrospective study	38%	Fibrosis stage remained stable (78.5%) in patients with SVR and increased (44%) in non-responders	24% overall did not complete therapy. 38% required the premature discontinuation of either IFN, RBV, or both agents
Carrión et al[81] (2007)	81	Randomized controlled trial	48% in early fibrosis and 18% in advanced fibrosis	Fibrosis progression -26% in treated group vs 70% in untreated group	Treatment interruption in 22% and 56% of patients with mild and advanced fibrosis respectively
Neff et al[86] (2004)	57	Retrospective study	24.5% virus negative at 48 wk	Responders to therapy trended toward improvement in level of fibrosis	Overall discontinuation rate 31.5%. Dose adjustments in 74%
Oton et al[87] (2006)	55	Prospective cohort study	43.60%	No improvement in fibrosis progression	29% discontinued due to intolerance
Samuel et al[83] (2003)	52	Randomized controlled trial	21%	No impact on fibrosis progression	Treatment interruption 43%
Fernández et al[82] (2006)	47	Prospective cohort study	23%	Significant histological improvement in 23%	Treatment interruption in 21%
Mukherjee et al[84] (2006)	39	Prospective cohort study	33.30%	Improved or stable fibrosis scores were also demonstrated in 66.7% of non-responder	43.6% discontinuation rates

SVR: Sustained virologic response; IFN: Interferon; RBV: Ribavarin.